USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: RELIABLE BIOPHARMACEUTICAL CORPORATION
City: ST. LOUIS
State: MO
Zip+4: 63114
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (314) 429-7700

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $350,000.00 6
SBIR Phase II $955,749.00 2
STTR Phase I $134,076.00 1

Award List:

ISOLATION OF BULK DEOXYNUCLEOSIDES FOR AIDS DRUGS

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00

ISOLATION OF BULK DEOXYNUCLEOSIDES FOR AIDS DRUGS

Award Year / Program / Phase: 1989 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $368,318.00
Abstract:
Several experimental anti-viral aids drugs (azt, ddc, dda) are based on chemically modified deoxynucleosides. these deoxynucleoside derivatives are made from ribonucleosides due to the unavailability of the deoxynucleosides at a reasonable cost. considering the need for anti-viral drugs and the… More

SYNTHESIS AND TESTING OF A NEW CLASS OF HEPARINOIDS

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Toce, Joseph A , Principal Investigator
Award Amount: $50,000.00
Abstract:
The goal of this project is to develop a therapeutic agent which would replace heparin. although heparin is the best drug for treatment of thromboembolic disease, it is unstable if administered orally and must therefore be administered by the intravenous or subcutaneous route. in addition, the… More

SYNTHESIS AND TESTING OF ANTIBIOTIC ANTISENSE CONJUGATES

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Phillip J Anevski
Award Amount: $50,000.00
Abstract:
The major goal of this project is to produce antisense-oligodeoxynucleotides that will readily be taken up by target cells. to accomplish this, we will attach antibiotics to antisense-oligodeoxynucleotides utilizing novel technologies. the antibiotics to be employed are readily taken up by… More

Regulators of Fibroblast Growth Factor Activity

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Phillip J. Anevski
Award Amount: $50,000.00
Abstract:
TELEPHONE NUMBER: (314) 429-7700 AWARDEE NUMBER: 1 R43 CA61390-01 The overall objective is to develop polysulfated carbohydrate derivatives that will inhibit the action of fibroblast growth factors (FGF). FGF's have been implicated in several human cancers both as angiogenic factors and as growth… More

Synthesis of Oxidant-Free Potassium Lactobionate

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph A. Toce
Award Amount: $50,000.00
Abstract:
The overall objective is to develop a process to produce lactobionic acid that is free of oxidizing components. Lactobionic acid is an essential component of perfusion solutions used to preserve organs for transplantation (Sumimoto, 1990). It functions as an impermeant and calcium chelator as well… More

Synthesis and testing of a new class of heparinoids

Award Year / Program / Phase: 1997 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $587,431.00

OLIGONUCLEOTIDES AS PRODRUGS FOR ANTICANCER DRUGS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Umashanker Sampath
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The overall objected is to develop an easy controlled method of delivery for anticancer nucleoside drugs [cytarabine (araC); cladribine] in their polymeric form as oligonucleotides. The monomer drugs, currently are delivered slowly through continuous infusion in… More

NEW INOTROPIC AGENTS FOR THE TREATMENT OF HEART FAILURE

Award Year / Program / Phase: 2002 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF CONNECTICUT HEALTH CENTER
Principal Investigator: Bruce T. Liang
Award Amount: $134,076.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The goal of the project is to develop new positive inotropes, represented by specifically modified AMP molecules. All of the currently available positive inotropic agents have significant adverse effects with digitalis being the only orally available positive… More